Ask AI
Case Challenge: Prostate Cancer

CE / CME

Biomarker Testing in Patients With Solid Tumors: Interactive Case Challenge for Prostate Cancer

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Released: May 18, 2026

Expiration: November 17, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following biomarker testing strategies should you discuss with a patient with metastatic prostate cancer to help inform them about their cancer, their potential prognosis, and treatment implications?

2.

I am very confident in my ability to identify actionable biomarkers in patients with prostate cancer following guideline-recommendations (ie, BRCA, HRR, MSI, HER2, and PSMA status) and to facilitate patient education and shared decision-making.

3.

Your patient is a 52-year-old man with newly diagnosed metastatic prostate cancer with a PSA of 50 ng/mL at baseline. While receiving treatment with abiraterone plus docetaxel, the patient reported increasing back pain and tenderness on the left leg. New or worsening bone metastases in femur and lower spine were confirmed on CT/bone scan. He had previously received biomarker testing at initial diagnosis, which indicated: MSI-stable, gBRCA2 wild type, and HER2-negative. Retesting of femur tissue biopsy indicates the following results: PALB2-positive, HER2-low (IHC 1+). Which of the following is a potential treatment option that has shown evidence of anti-tumor activity in clinical trials based on this patient’s molecular biomarker profile?